# SHUKRAMED share price & delivery % — NSE

> SHUKRAMED delivery % against its own history, 68 sessions of split-adjusted NSE prices since 2026, RSI and the 52-week range.

Canonical: https://patternsradar.com/s/SHUKRAMED

NSE · equity · [Healthcare](https://patternsradar.com/stocks/sector/healthcare.md) · [Pharmaceuticals & Biotechnology](https://patternsradar.com/stocks/industry/pharmaceuticals-biotechnology.md)

## At a glance

- SHUKRAMED closed at ₹84.16 on 20 Nov 2026, +2.36% on the day.
- Delivery was 49.1% of traded quantity on 20 Nov 2026, the 68th percentile of its own 68 sessions with a reading (20-session average 36.6%, 1-year average 40.3%).
- Market capitalisation is ₹3,700 crore, with no positive trailing earnings for a P/E.
- Q2 FY27 results (consolidated, filed 4 Nov 2026): revenue ₹44 crore, net profit ₹13 crore; the price moved 0.0% on the first session after.
- Promoters held 51.15% at 30 Sept 2026.

## Key data

The latest session's trading figures.

| Field | Value |
| --- | --- |
| Session | 2026-11-20 |
| Close (INR) | 84.16 |
| Change on the day (%) | +2.36% |
| Open (INR) | 81 |
| Day low (INR) | 80.3 |
| Day high (INR) | 84.8 |
| VWAP (INR) | 83.36 |
| Traded value (INR crore) | 33.87 |
| 52-week low (INR) | — |
| 52-week high (INR) | — |
| From 52-week high (%) | — |
| RSI (14) | 81.47 |
| ATR (14) | 3.44 |
| SMA 20 (INR) | 79.18 |
| SMA 50 (INR) | 68.77 |
| SMA 200 (INR) | — |
| Volume (shares) | 40.64L |
| Average volume, 20 sessions (shares) | 70.09L |
| Volatility, 1 year annualised (%) | 50.6% |
| Relative volume (× 20-day average) | 0.58× |
| Turnover (INR crore) | 33.87 |
| Industry | Pharmaceuticals |
| Peers | DIVISLAB LAURUSLABS SUNPHARMA ACUTAAS SAILIFE PPLPHARMA |

## Delivery percentage

Delivery is the share of traded quantity taken to demat rather than squared off the same day, measured here against this stock's own history.

Over the last 20 sessions SHUKRAMED settled 36.6% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 40.3%, so recent sessions are running 3.7 points lower than usual.

| Field | Value |
| --- | --- |
| Delivery, 2026-11-20 (%) | 49.09% |
| Delivery, 20-day average (%) | 36.57% |
| Delivery, 1-year average (%) | 40.32% |
| Delivery percentile against own history | 68th |
| Lowest 20-session average on record (%) | 7.93% |
| Highest 20-session average on record (%) | 71.23% |
| Sessions with a delivery reading | 68 |

[What delivery percentage measures](https://patternsradar.com/learn/delivery-percentage.md). [Scan the whole market on delivery](https://patternsradar.com/scans/delivery.md).

## Performance

| Period | Price return (%) |
| --- | --- |
| 1 day | +2.36% |
| 1 week | +2.35% |
| 1 month | +34.59% |
| 3 months | +94.23% |
| 6 months | — |
| 1 year | — |

## Bulk and block deals

The last 10 deals NSE disclosed for SHUKRAMED, newest first; the latest is dated 2026-10-29. A bulk deal is a client trading more than 0.5% of the company's shares in a day, a block deal a single large trade in the separate block window; quantities and prices are as published, not split-adjusted. The panel's CSV (https://patternsradar.com/csv/s/SHUKRAMED/deals.csv) has all 10 with value and remarks.

| Date | Deal | Side | Client | Quantity (shares) | Price (INR) |
| --- | --- | --- | --- | --- | --- |
| 2026-10-29 | bulk | Buy | QE SECURITIES LLP | 26.99L | 76.33 |
| 2026-10-29 | bulk | Sell | QE SECURITIES LLP | 26.92L | 76.4 |
| 2026-10-23 | bulk | Sell | HRTI PRIVATE LIMITED | 34.27L | 57.74 |
| 2026-10-23 | bulk | Buy | HRTI PRIVATE LIMITED | 33.69L | 56.81 |
| 2026-10-05 | bulk | Buy | HRTI PRIVATE LIMITED | 37.01L | 69.23 |
| 2026-10-05 | bulk | Sell | HRTI PRIVATE LIMITED | 33.95L | 69.19 |
| 2026-10-05 | bulk | Sell | QE SECURITIES LLP | 31.62L | 69.1 |
| 2026-10-05 | bulk | Buy | QE SECURITIES LLP | 31.08L | 68.78 |
| 2026-10-05 | bulk | Sell | ALPHAGREP SECURITIES PRIVATE LIMITED | 29.60L | 68.67 |
| 2026-10-05 | bulk | Buy | ALPHAGREP SECURITIES PRIVATE LIMITED | 29.60L | 68.63 |

## Valuation and growth

P/E is blank when trailing earnings are negative or unfiled, never a misleading number.

| Field | Value |
| --- | --- |
| Market cap (INR crore) | 3,699.8 |
| Free-float market cap (INR crore) | 1,807.4 |
| P/E (TTM) | — (no positive trailing earnings) |
| EPS (TTM, INR, split-adjusted) | — |
| Revenue (TTM, INR crore) | — |
| Net profit (TTM, INR crore) | — |
| Net margin (TTM, %) | — |
| Other income (% of PBT, TTM) | — |
| P/B | 31.39 |
| ROE (%) | — |
| Debt / equity | 0.19 |
| Shares outstanding (split-adjusted) | 44.08Cr |
| Listed on NSE | 2026-08-14 |
| Revenue growth YoY (%) | — |
| Revenue growth QoQ (%) | — |
| Profit growth YoY (%) | — |
| Profit growth QoQ (%) | — |
| Interest cost growth YoY (%) | — |

## Quarterly results

The last 1 quarters, consolidated basis, newest first. Every quarterly filing carries a profit and loss; the balance sheet and cash flow statement come only with the half-year and annual filings, and are in their own section. Rupee figures are in crore as filed; EPS and share counts are restated onto the split-adjusted basis the price series uses. Every quarter and every line item, on both bases, is in the [SHUKRAMED full history](https://patternsradar.com/s/SHUKRAMED/history.md).

| Quarter | Revenue (INR crore) | Revenue YoY (%) | Net profit (INR crore) | Profit YoY (%) | Net margin (%) | EPS basic (INR) |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 FY27 | 44.2 | — | 12.7 | — | 28.76% | 0.29 |

## Balance sheet and cash flow

The latest statements, newest first. From the half-year (September) and annual (March) results filings, the only ones that carry these statements: the balance sheet from September 2022, the cash flow from September 2020. Cash flows are year to date as filed, so an H1 row covers April to September. Rupee figures in crore; net debt, debt to equity and the current ratio are blank for banks, NBFCs and insurers, whose statements are not built that way.

### Balance sheet, consolidated

| Period | Total assets (INR crore) | Total equity (INR crore) | Borrowings (INR crore) | Net debt (INR crore) | Debt / equity | Current ratio |
| --- | --- | --- | --- | --- | --- | --- |
| H1 FY27 | 175.3 | 117.9 | 22.5 | 11.5 | 0.19 | 2.8 |

### Cash flow, consolidated

| Period | Months | Operating cash flow (INR crore) | Capex (INR crore) | Free cash flow (INR crore) | Dividends paid (INR crore) | Buybacks (INR crore) |
| --- | --- | --- | --- | --- | --- | --- |
| H1 FY27 | 6 | 0.4 | 15.6 | -15.1 | 0 | 0 |

## Reaction to results

The last 1 results. Close-to-close price change from the session before each results filing could trade; day 0 is the first session after it, and relative volume is day-0 volume against the 20 sessions before. Across all 1 results on record the price rose on day 0 after 0, with averages of 0% on day 0, +2.92% after 5 sessions and — after 20.

| Quarter | Filed | Day 0 (%) | +5 sessions (%) | +20 sessions (%) | Relative volume (×) |
| --- | --- | --- | --- | --- | --- |
| Q2 FY27 | 2026-11-04 | 0.00% | +2.92% | — | 0.57× |

## Shareholding pattern

The last 1 filings, newest first. Promoter change is in percentage points against the previous filing. Mutual funds and insurance are part of DII, FPI part of FII; retail and HNI are resident individuals either side of INR 2 lakh of share capital.

| Quarter end | Promoter (%) | Promoter change (pp) | Public (%) | FII (%) | DII (%) | Promoter pledged (%) | Mutual funds (%) | FPI (%) | Retail up to INR 2 lakh (%) |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-09-30 | 51.15% | — | 48.85% | 0.44% | 0.22% | 0% | 0% | 0.43% | 7.58% |

## Major holders

Every named holder on the pattern for the quarter ending 2026-09-30, largest first: every promoter-group member, and each public holder above 1%, as filed.

| Holder | Type | Holding (%) | Shares |
| --- | --- | --- | --- |
| RENUKA YOGESH PARIKH | Individual | 19.11% | 8.40Cr |
| ANAR PROJECT PRIVATE LIMITED | Promoter · Corporate | 18.71% | 8.22Cr |
| YOGESH BIHARILAL PARIKH | Individual | 17.56% | 7.72Cr |
| PARSHVA TEXCHEM INDIA PRIVATE LTD. | Promoter · Corporate | 17.38% | 7.64Cr |
| NAVKAR SURGICAL GUJARAT | Promoter · Corporate | 11.74% | 5.16Cr |
| DAKSHESH RAMESHCHANDRA SHAH | Promoter · Individual | 1.11% | 48.60L |
| ANAR JAYESHBHAI PATEL | Promoter · Individual | 0.99% | 43.60L |
| SUJAY JYOTINDRA MEHTA | Promoter · Individual | 0.71% | 31.20L |
| PAYAL SUJAY MEHTA | Promoter · Individual | 0.52% | 22.80L |

## Insider trades

No promoter, director or KMP of SHUKRAMED bought or sold in the open market in the last 90 days. No open-market promoter purchase is on record. From SEBI insider-trading disclosures, dated by the day NSE broadcast them, and counting open-market purchases and sales only. [How the insider figures are counted](https://patternsradar.com/learn/insider-trading.md).

## Results and dividend calendar

Dividend per share by Indian financial year (April to March), the last five:

| Financial year | Dividend per share (INR) |
| --- | --- |
| FY27 | ₹0.01 |

## Filings in the last 12 months

3 events from 2026 to 2026: results 1, shareholding 1, dividend 1 on record; the [SHUKRAMED full history](https://patternsradar.com/s/SHUKRAMED/history.md) lists them all. Dated by the day the company broadcast the filing; the price move is close to close on the first session that could trade it.

| Date | Kind | Filing | Price move, first session after (%) | Source |
| --- | --- | --- | --- | --- |
| 2026-11-04 | results | Results · Q2 FY27 · consolidated and standalone | 0.00% | https://nsearchives.nseindia.in/corporate/ixbrl/INTEGRATED_FILING_INDAS_209916_04112026210544_iXBRL_WEB.html |
| 2026-10-21 | shareholding | Shareholding · 30 Sept 2026 | -0.38% | https://nsearchives.nseindia.in/corporate/xbrl/SHP_1743144_21102026052139_WEB.xml |
| 2026-09-21 | dividend | Dividend · ₹0.01 per share | -1.07% | — |

## About the instrument

| Field | Value |
| --- | --- |
| Name | SHUKRAMED |
| Symbol | SHUKRAMED |
| Kind | equity |
| ISIN | INE551C01044 |
| Series | EQ |
| Listed on NSE | 2026-08-14 |
| Price history from | 2026-08-14 |
| Latest session | 2026-11-20 |
| Sessions | 68 |
| Macro sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic industry | Pharmaceuticals |
| F&O | no |
| Liquidity rank (20-day turnover) | 419 |

Delivery figures come from NSE's daily reports and are unavailable for older sessions. Prices are end-of-day, split- and bonus-adjusted, from the eod2 dataset. The NSE classification is the latest snapshot; the history since August 2026 is the `classification` records dataset.

## More in Pharmaceuticals & Biotechnology

| Symbol | Name | Industry | Close (INR) | Change on the day (%) | Turnover, 20-day average (INR crore) |
| --- | --- | --- | --- | --- | --- |
| [DIVISLAB](https://patternsradar.com/s/DIVISLAB.md) | Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | 11,180.5 | +0.02% | 884.2 |
| [LAURUSLABS](https://patternsradar.com/s/LAURUSLABS.md) | Laurus Labs Limited | Pharmaceuticals & Biotechnology | 2,294.6 | -0.49% | 695.4 |
| [SUNPHARMA](https://patternsradar.com/s/SUNPHARMA.md) | Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | 1,884.9 | -0.79% | 429 |
| [ACUTAAS](https://patternsradar.com/s/ACUTAAS.md) | Acutaas Chemicals Limited | Pharmaceuticals & Biotechnology | 3,833.5 | -3.61% | 356 |
| [SAILIFE](https://patternsradar.com/s/SAILIFE.md) | Sai Life Sciences Limited | Pharmaceuticals & Biotechnology | 1,800.7 | +0.69% | 352.3 |
| [PPLPHARMA](https://patternsradar.com/s/PPLPHARMA.md) | Piramal Pharma Limited | Pharmaceuticals & Biotechnology | 239.3 | -0.15% | 288.3 |
| [DRREDDY](https://patternsradar.com/s/DRREDDY.md) | Dr. Reddy's Laboratories Limited | Pharmaceuticals & Biotechnology | 1,390.2 | -0.76% | 266 |
| [GLENMARK](https://patternsradar.com/s/GLENMARK.md) | Glenmark Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | 2,648 | +1.51% | 231.6 |
| [AUROPHARMA](https://patternsradar.com/s/AUROPHARMA.md) | Aurobindo Pharma Limited | Pharmaceuticals & Biotechnology | 1,799 | -0.37% | 227.8 |
| [CIPLA](https://patternsradar.com/s/CIPLA.md) | Cipla Limited | Pharmaceuticals & Biotechnology | 1,415 | -0.25% | 217.7 |
| [ZYDUSLIFE](https://patternsradar.com/s/ZYDUSLIFE.md) | Zydus Lifesciences Limited | Pharmaceuticals & Biotechnology | 1,200 | -0.24% | 191.2 |
| [MANKIND](https://patternsradar.com/s/MANKIND.md) | Mankind Pharma Limited | Pharmaceuticals & Biotechnology | 2,665 | +1.37% | 180.9 |

[All Pharmaceuticals & Biotechnology stocks on the NSE](https://patternsradar.com/stocks/industry/pharmaceuticals-biotechnology.md) · [All Healthcare stocks on the NSE](https://patternsradar.com/stocks/sector/healthcare.md)

## Full history

The [SHUKRAMED full history](https://patternsradar.com/s/SHUKRAMED/history.md) has every quarter on both reporting bases with every line item, margins and per-share figures; every shareholding filing; the price reaction to every result; every dividend; every filing on record; and the price by year.

The interactive chart is on the rendered page: https://patternsradar.com/s/SHUKRAMED.

---

Price and delivery data from the [eod2](https://github.com/BennyThadikaran/eod2) dataset: National Stock Exchange of India end-of-day files, split- and bonus-adjusted, updated after each close. Not affiliated with or endorsed by NSE. PatternsRadar is a research tool. Nothing here is investment advice or a recommendation to buy or sell anything.
